loader2
Partner With Us NRI

Granules India Ltd share Price Today

Company details

465.70
480.00
281.35
485.95
6M Return 16.55%
1Y Return 59.08%
Mkt Cap.(Cr) 11,364.68
Volume 1,010,043
Div Yield 0.32%
OI
-
OI Chg %
-
Volume 1,010,043

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Granules India announced Q4FY24 results:

  • Revenue from Operations of Q4FY24 stood at Rs 11,758 million, a decline of 2% YoY.
  • Formulations including GPI manufactured products grew by 41%.
  • Revenue share from the North America increased to 70% in Q4FY24 as compared to 58% in Q4FY23.
  • Decline in Para API sales volume and price erosion.
  • Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 13%, and 73% of revenue from operations respectively for Q4FY24.
  • ROCE is at 16.5% as compared to 21.2% YoY.
  • Net debt stood at Rs 8,421 million and Net debt to EBITDA at 0.98x.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We had a strong uptick in gross margin for the Q4 and for the full year, with continued growth in formulations share coming from US and Europe as part of our global expansion strategy and a higher contribution from new products. While the fiscal year numbers were below expectations due to cyber incident and low paracetamol demand, we are very excited about the way our strategies for the future are playing out and look forward to the upcoming years.”

Result PDF

View Other Company Results

Granules India Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt

Weakness (2)

  • Degrowth in Revenue and Profit
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 477.4
R2 485.8
R3 491.7
Pivot

471.53

S1 463.1
S2 457.2
S3 448.8
EMA SMA
450.8
436.8
425.7
401.9
448.0
428.2
432.9
399.0
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY Bulk Purchase 2024-05-22 405.1 2593000 NSE
AXIS MUTUAL FUND Bulk Purchase 2024-05-22 405.1 2526000 NSE
KRISHNA PRASAD CHIGURUPATI Bulk Sell 2024-05-22 405.08 7500000 NSE
Name Category Shares
KRISHNA PRASAD CHIGURUPATI PROMOTER 34.78%
CHIGURUPATI UMA DEVI PROMOTER 3.81%
PRAGNYA CHIGURUPATI PROMOTER 0.76%
CHIGURUPATI PRIYANKA PROMOTER 0.75%
TYCHE INVESTMENTS PRIVATE LIMITED PROMOTER 1.47%

OUR RESEARCH VIEW

Investment recommendation
Formulation focus, backward integration to the fore…
Call Date
03 Jun 2024
Entry Price 418.00
Target Price 515.00
Duration
12 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Granules India Ltd Stocks COMPARISON

Financials( in Cr) Granules India Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 468.90 1,504.00 1,559.80 4,479.70 1,073.55
% Change -1.08 -1.11 -0.95 -1.86 -0.50
Mcap Cr 11,364.68 360,859.98 125,933.10 118,922.15 108,024.25
Revenue TTM Cr 3,764.92 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 412.76 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 28.34 36.46 29.85 75.71 28.16
1 Year Return 59.08 50.13 54.24 24.97 93.73
ROCE 19.33 16.79 14.76 19.30 16.25
ROE 19.07 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,586.53 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,341.08 2,221.69
LAST 3M 104,503.43 -28,029.53
LAST 6M 177,721.56 -12,795.34
LAST 12M 291,099.69 101,888.70

Granules India Ltd Information

Stock PE (TTM)
28.34
Promoter Holding
41.96%
Book Value
133.0843
ROCE
19.33%
ROE
19.07%
Description
  • Granules India Ltd. is an Indian pharmaceutical manufacturing company. Its product range consists of several off-patent drugs, such as ibuprofen, guaifenesin, metformin, and paracetamol. It was incorporated in 1984 with its headquarters in Hyderabad. The company’s quarterly consolidated net sales reported in June 2022 were Rs 1,019.56 crore, up 19.79% from Rs 849.85 crore in June 2021. On 12 August 2022, Granules India Ltd.’s market capitalisation was worth Rs 7,713 crore.  

    The company is listed on the Bombay Stock Exchange with the code 532482, and on the National Stock Exchange with the code GRANULES. It is also listed on the MCX Stock Exchange, Madras Stock Exchange, and Hyderabad Stock Exchange.  

    Granules India Ltd.’s product portfolio is diverse, featuring safe, effective, and high-quality drugs. It manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediaries (PFIs) with complete vertical integration. In the API sector, the company is among the largest manufacturers of first-line of defence products.  

    On 30 June 2022, Granules India Ltd.’s shareholding pattern indicated a 41.98% promoter stake, 23.13% foreign institutional investor stake, 3.03% domestic institutional investor stake, and 31.85% public stake. Promoters pledged 3.67% shares in the June quarter, making the total pledge of promoter holdings stand at 10.59%. Dr Krishna Prasad Chigurupati was the leading promoter with a 34.8% share. He is the company’s chairman and managing director. During the June 2022 quarter, mutual funds decreased holdings from 3.77% to 3.03%.  

    The company’s top management comprises Dr K V S Ram Rao, Mrs Uma Devi Chigurupati, Mr Arun Rao Akinepally, Dr Saumen Chakraborty, Mrs Sucharita Rao Palepu, Mr Arun Sawhney, Mr Robert George Cunard, Mr K B Sankar Rao, and Mr Harsha Chigurupati. The auditors are B S R & Associates LLP. On 30 June 2022, the company disclosed a total of 24.80 crore shares outstanding.  

    Granules India Ltd.’s share price closed at Rs 310.45 on BSE on 12 August 2022. It closed at Rs 310.65 on NSE. The 52-week high for Granules India Ltd.’s share price was Rs 374.70, and the 52-week low for the company’s share price was Rs 227.  

    The company’s peers include Divis Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Glenmark Pharmaceuticals Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Second Floor Block III, My Home Hub Madhapur, Hyderabad, Telangana, 500081

Tel : 91-40-66760000
Email : investorrelations:granulesindia.com; mail:granules
Website : http://www.granulesindia.com
Registrar

CIL Securities Limited

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532482
NSE Code : GRANULES
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE101D01020

FAQ’s on Granules India Ltd Shares

You can buy Granules India Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Granules India Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 19, 2024 04:03 PM the closing price of Granules India Ltd was Rs.468.90.

The latest PE ratio of Granules India Ltd as of Jun 19, 2024 04:03 PM is 28.34

The latest PB ratio of Granules India Ltd as of Jun 19, 2024 04:03 PM is 0.28

The 52-week high of Granules India Ltd share price is Rs. 485.95 while the 52-week low is Rs. 281.35

According to analyst recommendations, Granules India Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 19, 2024 04:03 PM, the market cap of Granules India Ltd stood at Rs. 11,364.68.

Download App

Download Our App

Play Store App Store
market app